Methacholine and Salbutamol Combination

Methacholine and salbutamol represent a combination used in clinical settings, primarily for diagnostic purposes rather than as a therapeutic combination. Methacholine, a parasympathomimetic bronchoconstrictor, is used as a diagnostic agent to induce bronchoconstriction in methacholine challenge tests to diagnose bronchial hyperreactivity in subjects who do not have clinically apparent asthma. It works by narrowing bronchial airways through activation of muscarinic receptors in the lungs. Salbutamol (also known as albuterol), a moderately selective beta(2)-receptor agonist, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. In the context of methacholine challenge tests, salbutamol is used to reverse the bronchoconstriction induced by methacholine. The relationship between these drugs is antagonistic: methacholine induces bronchoconstriction while salbutamol reverses it. This relationship is utilized in clinical settings for methacholine challenge testing, where salbutamol is used to reverse the effect if necessary. It is also used in bronchoprotective effect studies, where salbutamol can be administered before methacholine to study its protective effect against bronchoconstriction. Furthermore, this combination is used in comparative studies to evaluate the effectiveness of different delivery systems and formulations of bronchodilators, such as comparing Salbutamol Easyhaler to Ventoline Evohaler with spacer for relieving methacholine-induced bronchoconstriction.

Other names

Albuterol